ReviewCancers2020
Tamoxifen and Endometrial Cancer: A Janus-Headed Drug.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose-response meta-analysis.Cancer reports (Hoboken, N.J.) · 2023Pooled it
- Integrated Clinicogenomic Risk Modeling for Metachronous Second Primary Cancers.medRxiv : the preprint server for health sciences · 2026Article
- Carcinogenic Medications: A Review of Specific Agents and Molecular Mechanisms of Carcinogenesis.Cancer reports (Hoboken, N.J.) · 2026Review
- Can machine learning predict endometrial cancer in patients with postmenopausal uterine bleeding?Przeglad menopauzalny = Menopause review · 2026Article
- Synergistic combinatorial anticancer potential of Tamoxifen with Naringin and Diosmetin in MCF-7 breast cancer cells and their liposomal delivery.Scientific reports · 2026Article
- Secondary cancers in breast cancer survivors. A two-centre study.Archives of medical science : AMS · 2026Article
- Pharmacotherapeutic considerations of selective estrogen receptor modulators for vascular protection.Frontiers in pharmacology · 2026Review
- Oxidative DNA damage induced by 3,4-diOH-TAM, a tamoxifen metabolite, in relation to endometrial carcinogenesis.Scientific reports · 2025Article
- Transcriptional coregulator ZMIZ1 modulates estrogen responses that are essential for healthy endometrial function.The Journal of clinical investigation · 2025Article
- Comparative Study of Ferrocene- and Indene-Based Tamoxifen Derivatives of Different Molecular Flexibility on High-Mortality Cancer Cell Lines.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- Virtual screening,Toxicology reports · 2025Article
- Alleviating Effects of Vitamins E and D on Tamoxifen-Induced Hepatotoxicity in Female Wistar Rats.Chonnam medical journal · 2025Article
- Revolutionizing Implantation Studies: Uterine-Specific Models and Advanced Technologies.Biomolecules · 2025Review
- Machine learning Nomogram for Predicting endometrial lesions after tamoxifen therapy in breast Cancer patients.Scientific reports · 2025Article
- Endometrial carcinosarcoma in a young female with absence of established risk factors: a case report.Frontiers in oncology · 2025Article
- Epidemiology, molecular typing, microbiome-immune interactions and treatment strategies of endometrial cancer: a review.Frontiers in immunology · 2025Review
- High-Risk Breast Clinic.Journal of the advanced practitioner in oncology · 2025Article
- Endocrine therapy for endometrial cancer: traditional approaches and novel targets.Frontiers in oncology · 2025Review
- Exploring the effects of estrogen deficiency and aging on organismal homeostasis during menopause.Nature aging · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tamoxifen is a selective estrogen receptor modulator used for the treatment and prevention of estrogen receptor (ER)-positive breast cancer. However, tamoxifen increases the risk of endometrial cancer (EC) by about 2-7 fold, and more aggressive types of EC with poor prognoses are observed in tamoxifen users. On the other hand, tamoxifen is an efficacious treatment for advanced or recurrent EC with low toxicity. The differential agonistic or antagonistic effects of tamoxifen on ERα are explained by the tissue-specific expression profiles of co-activators and co-repressors of the receptor. The estrogen-agonistic effect of tamoxifen in endometrial cancers can also be explained by the expression of G-protein coupled estrogen receptor 1 (GPER-1), a membrane-bound estrogen receptor for which tamoxifen and other "antiestrogens" are pure agonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.